Can a sedative calm the Body's stress response during brain tumor surgery?

NCT ID NCT05005715

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving the sedative dexmedetomidine during pituitary tumor surgery can dampen the body's stress response and improve early recovery. About 64 adults with non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery will be randomly assigned to receive either dexmedetomidine or a placebo (saline) intravenously during the procedure. Researchers will measure recovery quality using a standard questionnaire and track hormone levels related to stress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dexmedetomidine, a sedative drug given intravenously during surgery
What this could lead to
If it works, this could point toward a way to help patients recover more comfortably after pituitary tumor surgery.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Dexmedetomidine can cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-FUNCTIONING PITUITARY ADENOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.